Literature DB >> 17934816

Efficacy of loco-regional ablation therapy of HCC in a population of liver transplanted patients.

Filomena Morisco1, Rosa Stigliano, Andrew Godfrey, Gioacchino Leandro, David Patch, Brian Davidson, Keith Rolles, Arjun Dhillon, Amar Paul Dhillon, Alberto Quaglia, Andrew Kenneth Burroughs.   

Abstract

BACKGROUND AND
OBJECTIVE: Loco-ablation therapy (LAT) has become standard treatment for patients with HCC who are candidates for liver transplantation (LT). The aim of this study was: to evaluate if LAT was able to induce complete necrosis of tumour mass; to determine the tumour recurrence rate after LT and factors associated with recurrence. PATIENTS: The percentage and the distribution of necrosis in 116 HCC nodules of 61 patients with (26 patients) and without (35 patients) previous types of LAT were examined in explanted livers.
RESULTS: Total necrosis was found only in 7% of treated nodules, and 42% of these showed absence of necrosis. The amount of necrosis was significantly related to the gross appearance of HCC: a single nodule with smaller adjacent satellite nodules showed a higher percentage of necrosis. No relation was found between the amount of necrosis and the type of LAT. Recurrence was observed in 11.5% and 8.5% of patients with and without previous LAT, respectively (P = ns).
CONCLUSIONS: LAT very rarely induces complete necrosis; the amount of necrosis seems to depend on the growth pattern of the tumour and not on the type of previous LAT; the tumour size, measured at explant, is the only variable significantly related to recurrence.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17934816     DOI: 10.1007/s10620-007-9986-y

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  29 in total

1.  Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies.

Authors:  H A EDMONDSON; P E STEINER
Journal:  Cancer       Date:  1954-05       Impact factor: 6.860

Review 2.  Surgery and portal hypertension.

Authors:  C G Child; J G Turcotte
Journal:  Major Probl Clin Surg       Date:  1964

Review 3.  Blood supply of early hepatocellular carcinoma.

Authors:  S Bhattacharya; B Davidson; A P Dhillon
Journal:  Semin Liver Dis       Date:  1995-11       Impact factor: 6.115

4.  Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival.

Authors:  F Y Yao; L Ferrell; N M Bass; J J Watson; P Bacchetti; A Venook; N L Ascher; J P Roberts
Journal:  Hepatology       Date:  2001-06       Impact factor: 17.425

Review 5.  Hepatocellular carcinoma.

Authors:  K Okuda
Journal:  J Hepatol       Date:  2000       Impact factor: 25.083

6.  Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation.

Authors:  J M Llovet; X Mas; J J Aponte; J Fuster; M Navasa; E Christensen; J Rodés; J Bruix
Journal:  Gut       Date:  2002-01       Impact factor: 23.059

7.  Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis.

Authors:  S Jonas; W O Bechstein; T Steinmüller; M Herrmann; C Radke; T Berg; U Settmacher; P Neuhaus
Journal:  Hepatology       Date:  2001-05       Impact factor: 17.425

8.  Treatment of hepatocellular carcinoma with radiofrequency ablation: radiologic-histologic correlation during follow-up periods.

Authors:  Manabu Morimoto; Kazuya Sugimori; Kazuhito Shirato; Atsushi Kokawa; Naohiko Tomita; Takafumi Saito; Noriko Tanaka; Akinori Nozawa; Masamichi Hara; Hisahiko Sekihara; Hiroshi Shimada; Toshio Imada; Katsuaki Tanaka
Journal:  Hepatology       Date:  2002-06       Impact factor: 17.425

9.  Underestimation of the influence of satellite nodules as a risk factor for post-transplantation recurrence in patients with small hepatocellular carcinoma.

Authors:  Aurélie Plessier; Liana Codes; Yann Consigny; Daniele Sommacale; Federica Dondero; Alexandre Cortes; Françoise Degos; Pierre-Yves Brillet; Valérie Vilgrain; Valérie Paradis; Jacques Belghiti; François Durand
Journal:  Liver Transpl       Date:  2004-02       Impact factor: 5.799

10.  Underestimation of nodules while staging hepatocellular carcinoma prior to neoadjuvant treatment on waiting list for transplantation.

Authors:  D L Stippel; H U Kasper; K Schleimer; C Benz; A H Hölscher; K T E Beckurts
Journal:  Transplant Proc       Date:  2003-06       Impact factor: 1.066

View more
  4 in total

1.  Bridge treatments of hepatocellular carcinoma in cirrhotic patients submitted to liver transplantation.

Authors:  Maurizio Pompili; Giampiero Francica; Gian Ludovico Rapaccini
Journal:  Dig Dis Sci       Date:  2008-08-21       Impact factor: 3.199

Review 2.  Liver transplantation as a management of hepatocellular carcinoma.

Authors:  Ayman Zaki Azzam
Journal:  World J Hepatol       Date:  2015-06-08

Review 3.  Liver transplantation for hepatocellular carcinoma.

Authors:  Sudeep Tanwar; Shahid A Khan; Vijay Paul Bob Grover; Catherine Gwilt; Belinda Smith; Ashley Brown
Journal:  World J Gastroenterol       Date:  2009-11-28       Impact factor: 5.742

4.  Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy.

Authors:  David J Pinato; Sam M Murray; Alejandro Forner; Takahiro Kaneko; Petros Fessas; Pierluigi Toniutto; Beatriz Mínguez; Valentina Cacciato; Claudio Avellini; Alba Diaz; Rosemary J Boyton; Daniel M Altmann; Robert D Goldin; Ayse U Akarca; Teresa Marafioti; Francesco A Mauri; Edoardo Casagrande; Federica Grillo; Edoardo Giannini; Sherrie Bhoori; Vincenzo Mazzaferro
Journal:  J Immunother Cancer       Date:  2021-09       Impact factor: 13.751

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.